Limin Zheng

Limin Zheng

Auto-generated profile, based on publicly available information

Limin Zheng

MOE Key Laboratory of Gene Function and Regulation, School of Life Sciences, Sun Yat-sen University, Guangzhou, China

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 May 2009 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
DKDong-Ming Kuang
Dong-Ming Kuang
QZQiyi Zhao
Qiyi Zhao
CPChen Peng
Chen Peng
JXJing Xu
Jing Xu
JZJing-Ping Zhang
Jing-Ping Zhang
LZLimin Zheng
Limin Zheng
Macrophages (Mφ) are prominent components of solid tumors and exhibit distinct phenotypes in different microenvironments. We have recently found that tumors can alter the normal developmental process of Mφ to trigger transient activation of monocytes in peritumoral stroma. We showed that a fraction of monocytes/Mφ in peritumoral stroma, but not in cancer nests, expresses surface PD-L1 (also termed B7-H1) molecules in tumors from patients with hepatocellular carcinoma (HCC). Monocytes activated by tumors strongly express PD-L1 proteins with kinetics similar to their activation status, and significant correlations were found between the levels of PD-L1+ and HLA-DRhigh on tumor-infiltrating monocytes. Autocrine tumor necrosis factor α and interleukin 10 released from activated monocytes stimulated monocyte expression of PD-L1. The PD-L1+ monocytes effectively suppressed tumor-specific T cell immunity and contributed to the growth of human tumors in vivo; the effect could be reversed by blocking PD-L1 on those monocytes. Moreover, we found that PD-L1 expression on tumor-infiltrating monocytes increased with disease progression, and the intensity of the protein was associated with high mortality and reduced survival in the HCC patients. Thus, expression of PD-L1 on activated monocytes/Mφ may represent a novel mechanism that links the proinflammatory response to immune tolerance in the tumor milieu.

1 February 2011 in Cancer Cell
Verified
Journal Article
Closed access
JHJin Hou
Jin Hou
LLLi Lin
Li Lin
WZWeiping Zhou
Weiping Zhou
ZWZhengxin Wang
Zhengxin Wang
GDGuoshan Ding
Guoshan Ding
XCXuetao Cao
Xuetao Cao

1 May 2009 in Journal of Hepatology
Verified
Journal Article
Closed access
JZJing-Ping Zhang
Jing-Ping Zhang
JYJing Yan
Jing Yan
JXJing Xu
Jing Xu
XPXiong-Hao Pang
Xiong-Hao Pang
MCMin-Shan Chen
Min-Shan Chen
LZLimin Zheng
Limin Zheng

1 May 2011 in Journal of Hepatology
Verified
Journal Article
Closed access
DKDong-Ming Kuang
Dong-Ming Kuang
QZQiyi Zhao
Qiyi Zhao
YWYan Wu
Yan Wu
CPChen Peng
Chen Peng
JWJianen Wang
Jianen Wang
LZLimin Zheng
Limin Zheng

1 May 2016 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
XXXiao Xiao
Xiao Xiao
XLXiang-Ming Lao
Xiang-Ming Lao
MCMin-Min Chen
Min-Min Chen
RLRui-Xian Liu
Rui-Xian Liu
YWYuan Wei
Yuan Wei
DKDong-Ming Kuang
Dong-Ming Kuang
B cells often constitute abundant cellular components in human tumors. Regulatory B cells that are functionally defined by their ability to produce IL10 downregulate inflammation and control T-cell immunity. Here, we identified a protumorigenic subset of B cells that constitutively expressed higher levels of programmed cell death-1 (PD-1) and constituted ∼10% of all B cells in advanced-stage hepatocellular carcinoma (HCC). These PD-1hi B cells exhibited a unique CD5hiCD24−/+CD27hi/+CD38dim phenotype different from the phenotype of conventional CD24hiCD38hi peripheral regulatory B cells. TLR4-mediated BCL6 upregulation was crucial for PD-1hi B-cell induction by HCC environmental factors, and that effect was abolished by IL4-elicited STAT6 phosphorylation. Importantly, upon encountering PD-L1+ cells or undergoing PD-1 triggering, PD-1hi B cells acquired regulatory functions that suppressed tumor-specific T-cell immunity and promoted cancer growth via IL10 signals. Our findings provide significant new insights for human cancer immunosuppression and anticancer therapies regarding PD-1/PD-L1. Significance: We identify a novel protumorigenic PD-1hi B-cell subset in human HCC that exhibits a phenotype distinct from that of peripheral regulatory B cells. TLR4-mediated BCL6 upregulation is critical for induction of PD-1hi B cells, which operate via IL10-dependent pathways upon interacting with PD-L1 to cause T-cell dysfunction and foster disease progression. Cancer Discov; 6(5); 546–59. ©2016 AACR. See related commentary by Ren et al., p. 477. This article is highlighted in the In This Issue feature, p. 461

1 July 2015 in The Lancet Oncology
Verified
Journal Article
Closed access
XLXue-Jia Lin
Xue-Jia Lin
YCYutian Chong
Yutian Chong
ZGZhi-Wei Guo
Zhi-Wei Guo
CXChen Xie
Chen Xie
XYXiao-Jing Yang
Xiao-Jing Yang
SZShi-Mei Zhuang
Shi-Mei Zhuang